Who Paid My Doc
Jillian Rosengard
Clinical Neurophysiology Bronx, NY Medical Doctor
NPI 1528320397 CMS profile 1402053
111 E 210Th St Dept Of, Bronx, NY 10467
General payments
$1,221
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Jillian Rosengard of Bronx, NY is reported in the CMS Open Payments database as having received $1,221 across 30 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 49th percentile of Clinical Neurophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $260 | 2 | |
| 2024 | General | $200 | 1 | |
| 2023 | General | $187 | 3 | |
| 2022 | General | $150 | 3 | |
| 2020 | General | $103 | 5 | |
| 2019 | General | $321 | 16 |
Beside peers
- Jillian Rosengard
- Clinical Neurophysiology median
- Middle half of Clinical Neurophysiology
- National median
In program year 2025, general payments to Jillian Rosengard were reported at $260. Among 259 Clinical Neurophysiology profiles paid that year, the median was $435 and the middle half received between $121 and $1,917.
Show as a table
| Year | Jillian Rosengard | Clinical Neurophysiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $321 | $306 | $88–$1,636 | $163 |
| 2020 | $103 | $299 | $85–$1,847 | $114 |
| 2021 | $0 | $325 | $96–$2,308 | $132 |
| 2022 | $150 | $395 | $106–$1,957 | $149 |
| 2023 | $187 | $388 | $120–$1,718 | $160 |
| 2024 | $200 | $471 | $137–$1,931 | $164 |
| 2025 | $260 | $435 | $121–$1,917 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 30 drugsPart D claims
1,322
Drug cost
$434,132
Branded share of claims
21.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Epidiolex Cannabidiol (Cbd) | Brand | 23 | $135,510 | |
| Xcopri Cenobamate | Brand | 37 | $59,979 | |
| Banzel Rufinamide | Brand | 19 | $53,814 | |
| Briviact Brivaracetam | Brand | 15 | $30,104 | |
| Trokendi Xr Topiramate | Brand | 11 | $25,150 | |
| Rufinamide | Generic | 28 | $23,183 | |
| Lacosamide | Generic | 169 | $19,857 | |
| Vimpat Lacosamide | Brand | 20 | $17,874 | |
| Qulipta Atogepant | Brand | 13 | $13,875 | |
| Nurtec Odt Rimegepant Sulfate | Brand | 13 | $13,203 |
The 10 drugs with the highest cost, of 30 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 16 billing codesPaid by Medicare
$32,952
Medicare patients
138
Services billed
296
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Diabetes | 62% | |
| Arthritis | 48% | |
| Depression | 43% | |
| Ischemic heart disease | 41% | |
| Alzheimer's or dementia | 41% | |
| Heart failure | 40% | |
| Chronic kidney disease | 40% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
30 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Clinical Neurophysiology in New York
Alcibiades Rodriguez
Clinical Neurophysiology · New York, NY
Farhad Kadkhodaei Elyaderani
Clinical Neurophysiology · Bronx, NY
Jessica Robinson-Papp
Clinical Neurophysiology · New York, NY
Mohini Gurme
Clinical Neurophysiology · West Nyack, NY
Cecily Anto
Clinical Neurophysiology · Hauppauge, NY
Itzhak Haimovic
Clinical Neurophysiology · Great Neck, NY
Related records
Clinical Neurophysiology in New York
Practitioners in the same specialty and state, ranked by reported value.
All Clinical Neurophysiology
Everyone recorded under this specialty, nationwide.
Doctors in New York
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.